$0.74
Today
as of Aug 5, 16:47 ET
Last 30 days
Recent Press Releases & News
CalciMedica Reaches FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review
Overview
52-week range
$0.46
$7.20
4% of range
Avg surprise (last 3)
+12.6%
Avg reaction (last 2)
+2.9%
50% positive
Latest IV / EM
251%
EM ±18.1% · $1 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.22 | $-0.28 | +21.4% | +38.9% | +6.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.52 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.40 | $-0.40 | 0.0% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.36 | $-0.43 | +16.3% | — | -0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.50 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.36 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.01 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.82 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.11 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.33 | -$0.40 | +17.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | — | $-6M | $-7M | $-6M | — | $-6M | $-7M |
| Net income | $5M | — | $-8M | $-6M | $-5M | — | $-6M | $-4M |
| EPS (diluted) | $0.30 | — | $-0.52 | $-0.40 | $-0.36 | — | $-0.50 | $-0.36 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8M | $12M | $5M | $6M | $13M | $8M | $9M | $5M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $9M | $14M | $15M | $19M | $25M | $20M | $16M | $20M |
| Total assets | $9M | $14M | $15M | $19M | $25M | $20M | $16M | $21M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $10M | $20M | $15M | $13M | $14M | $5M | $7M | $7M |
| Total equity | $-1M | $-7M | $-268,000 | $6M | $11M | $14M | $9M | $14M |